Loading...
•
Jun 25, 2022
Henry Schein Q2 2022 Earnings Report
Reported record financial results for the second quarter of 2022.
Key Takeaways
Henry Schein reported a 2.1% increase in net sales, reaching $3.0 billion. GAAP diluted EPS increased to $1.16, compared to $1.10 in the second quarter of 2021. The company reaffirmed its full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91.
Second-quarter net sales reached $3.0 billion, a 2.1% increase compared to Q2 2021.
Internal sales grew by 6.7% in local currencies, excluding PPE and COVID-19 related products.
GAAP diluted EPS was $1.16, compared to $1.10 in Q2 2021.
The company reaffirmed its full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91.
Henry Schein
Henry Schein
Henry Schein Revenue by Segment
Henry Schein Revenue by Geographic Location
Revenue by Segment
Global Dental Revenue
CapyFin.comGlobal Medical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Distribution and Value-Added Services Revenue
CapyFin.comInternational Distribution and Value-Added Services Revenue
CapyFin.com Forward Guidance
Henry Schein affirmed its full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91 and updated full-year 2022 expected sales growth to be approximately 3% to 6% over 2021.
Positive Outlook
- Affirms guidance for full-year 2022 GAAP diluted EPS attributable to Henry Schein, Inc. of $4.75 to $4.91.
- Reflects growth of 7% to 10% compared with 2021 GAAP diluted EPS of $4.45
- Reflects growth of 5% to 9% compared with 2021 non-GAAP diluted EPS of $4.52.
- Assumes that foreign currency exchange rates will remain generally consistent with current levels
- Assumes that end markets will remain stable and consistent with current market conditions
Challenges Ahead
- Updates full-year 2022 expected sales growth to be approximately 3% to 6% over 2021.
- Reflects adverse effects from foreign exchange rates
- Reflects a decrease in anticipated sales of PPE and COVID-related products, including COVID-19 test kits.
- Sales of COVID-19 test kits are now expected to decline 25% to 30% from 2021
- Assumes that there are no material adverse market changes associated with COVID-19.
Revenue & Expenses
Visualization of income flow from segment revenue to net income